{
  "issued_date": "2012-04-25", 
  "original_url": "http://www.mhra.gov.uk/Publications/Safetywarnings/MedicalDeviceAlerts/CON149825", 
  "doc_details": {
    "Type": "Medical Device Alert", 
    "Series No": "MDA/2012/022", 
    "Audience": "Healthcare professionals", 
    "Published": "25 April 2012 at 14:00", 
    "Format": "Electronic only", 
    "Size": "A4", 
    "Pages": "9", 
    "Price": "Free", 
    "ISBN/ISSN": "", 
    "Author": "", 
    "Copyright": "Crown"
  }, 
  "_assets": [
    {
      "content_type": "application/pdf", 
      "title": "Dear Doctor Letter", 
      "assetid": 0, 
      "original_url": "http://www.mhra.gov.uk/home/groups/comms-po/documents/news/con149798.pdf", 
      "filename": "downloads/8ca6cac219998d50977fa7851c735c66006195da/con149798.pdf", 
      "original_filename": "con149798.pdf"
    }, 
    {
      "content_type": "application/pdf", 
      "title": "Information for your radiologist ", 
      "assetid": 1, 
      "original_url": "http://www.mhra.gov.uk/home/groups/dts-bs/documents/medicaldevicealert/con149832.pdf", 
      "filename": "downloads/66edf5ce2395a969e1fc05cda65e3983dfdce652/con149832.pdf", 
      "original_filename": "con149832.pdf"
    }
  ], 
  "body": "## Device\n\nDermal filler for breast augmentation.\n\nMacrolane\u2122 Volume Restoration Factor (VRF).\n\nManufactured by Q-Med AB (a Galderma division).\n\nMacrolane VRF20 and VRF30 is an injectable filler for volume restoration and body contouring in a range of indications including breast augmentation.\n\n## Problem\n\nUse of Macrolane VRF20 and Macrolane VRF30 for breast augmentation can make diagnosis of breast cancer more difficult, particularly with the use of mammography.  \n  \nThe MHRA has been made aware of a [ASSET_TAG](#ASSET0) (160Kb) issued in April 2012 to clinicians by Q-Med about the use of Macrolane recommending that it is not used for injection into breasts because it can make diagnosis of breast cancer more difficult, particularly during mammography.  \n  \nThe manufacturer has stated:  \n\u2018Macrolane is detectable in mammography, ultrasound examination and MRI examination of the breasts.  \n  \nMammograms  \nA clinical study indicates that the presence of Macrolane may significantly reduce the diagnostic quality of mammograms, since Macrolane will appear as a gray/white shadow in the mammogram. In this case ultrasound can be used as a complementary examination.  \n  \nUltrasound  \nUltrasound can be used to diagnose lumps in the breast after a Macrolane treatment. Ultrasound may also be a complement to mammography at breast screening and diagnosing. Some radiologists explain that Macrolane has a typical appearance in an ultrasound, similar to that of water, but with a snowstorm appearance.\u2019  \n  \n[Breast diagnostics and Marolane](http://www.q-medpractitioner.com/International/Macrolane/Radiologists/) (external link)  \n  \nThere is no association with cancer and no safety concerns have been identified for this product. The product remains on the market for use elsewhere in the body. \u00a0The manufacturer plans to issue updated instructions for use in due course with updated indications for Macrolane use.  \n\n\n## Action\n\nDo not use Macrolane for breast augmentation.  \n  \nHave procedures in place for radiographers to check with patients presenting for breast examination for any history of breast injection. \u00a0Staff should request the card (appendix 1) that the patient was given at the time of injection, identifying Macrolane as the product used, and pass it on to the examining radiologist.  \n  \nWomen may present with concerns that the injected Macrolane has affected mammogram results. GPs may wish to consider referral for repeat imaging. \u00a0  \n  \n\n\n### Action by  \n  \n  * Breast surgeons  \n  * Cosmetic surgeons  \n  * GPs  \n  * Mammographers  \n  * Plastic surgeons  \n  * Radiographers  \n  * Radiologists  \n  \n## Distribution\n\nThis MDA has been sent to:  \n  \n  * NHS trusts in England (chief executives)  \n  * Care Quality Commission (CQC) (Headquarters) for information  \n  * HSC trusts in Northern Ireland (chief executives)  \n  * NHS boards in Scotland (equipment coordinators)  \n  * Local authorities in Scotland (equipment coordinators)  \n  * NHS boards and trusts in Wales (chief executives)  \n  * Primary care trusts in England (chief executives)  \n  \n### Onward distribution\n\nPlease bring this notice to the attention of relevant employees in your establishment. Below is a suggested list of recipients.\n\nTrusts  \nCAS and SABS (NI) liaison officers for onward distribution to all relevant staff includingtion to all relevant staff including:  \n  \n  * Breast nurse specialists  \n  * Breast screening units  \n  * Breast surgeons  \n  * Clinical governance leads  \n  * General surgeons  \n  * General surgery  \n  * General surgical units, directors of  \n  * Mammography units  \n  * Medical directors  \n  * Medical oncologists  \n  * Medical oncology, directors of  \n  * Nursing executive directors  \n  * MRI units, directors of  \n  * Outpatient clinics  \n  * Plastic surgeons  \n  * Radiographer superintendents  \n  * Radiographers  \n  * Radiologists  \n  * Radiology departments  \n  * Radiology directors  \n  * Risk managers  \n  \nPrimary care trusts  \nCAS liaison officers for onward distribution to all relevant staff including:  \n  \n  * Directors of public health  \n  * General practitioners  \n  \n\n\n### Independent distribution\n\nEstablishments registered with the Care Quality Commission (CQC) (England only)\n\nThis alert should be read by:  \n  \n  * Clinics  \n  * Cosmetic surgeons  \n  * Hospitals in the independent sector  \n  * Independent treatment centres  \n  * Private medical practitioners  \n  \nPlease note: CQC and OFSTED do not distribute these alerts. Independent healthcare providers and social care providers can sign up to receive MDAs directly from the Department of Health\u2019s Central Alerting System (CAS) by sending an email to: [safetyalerts@dh.gsi.gov.uk](mailto:safetyalerts@dh.gsi.gov.uk) and requesting this facility.\n\n## Manufacturer Contact\n\nDavid Wall  \nDirector of Sales & Marketing, Q-Med, OTC & Ireland  \nGalderma UK & Ireland  \nMeridien House  \n69-71 Clarendon Road  \nWatford  \nWD17 1DS  \n  \nTel: 01923 208 950  \nFax: 01923 208 998  \nEmail: [David.wall@galderma.com](mailto:David.wall@galderma.com)\n\n## Feedback\n\nIf you have any comments or feedback on this Medical Device Alert please email us at: [dts@mhra.gsi.gov.uk](mailto:dts@mhra.gsi.gov.uk)\n\n## Appendix\n\n[ASSET_TAG](#ASSET1) (236Kb) \n\n## England\n\nIf you are in England, please send enquiries about this notice to the MHRA, quoting reference number MDA/2012/022 or 2012/004/023/291/010.\n\nTechnical aspects  \nMiss Feza Haque or Mr Ian Smith  \nMedicines & Healthcare products Regulatory Agency  \nFloor 4  \n151 Buckingham Palace Road  \nLondon SW1W 9SZ\n\nTel: 020 3080 7066 / 7306  \nFax: 020 8754 3965  \nEmail: [feza.haque@mhra.gsi.gov.uk](mailto:feza.haque@mhra.gsi.gov.uk) or [ian.smith@mhra.gsi.gov.uk](mailto:ian.smith@mhra.gsi.gov.uk)\n\nClinical aspects  \nDr Nicola Lennard  \nMedicines & Healthcare products Regulatory Agency  \nFloor 4  \n151 Buckingham Palace Road  \nLondon SW1W 9SZ\n\nTel: 020 3080 7126  \nFax: 020 8754 3965  \nEmail: [nicola.lennard@mhra.gsi.gov.uk](mailto:nicola.lennard@mhra.gsi.gov.uk)\n\n### How to report adverse incidents\n\nPlease report via our website: [Reporting adverse incidents involving medical devices](http://www.mhra.gov.uk/Safetyinformation/Reportingsafetyproblems/Devices/index.htm)  \nFurther information about CAS can be found [on the CAS website](https://www.cas.dh.gov.uk/Home.aspx) (external link)\n\n## Northern Ireland\n\nAlerts in Northern Ireland will continue to be distributed via the NI SABS system.\n\nEnquiries and adverse incident reports in Northern Ireland should be addressed to:\n\nNorthern Ireland Adverse Incident Centre  \nHealth Estates Investment Group  \nRoom 17  \nAnnex 6  \nCastle Buildings  \nStormont Estate  \nDundonald BT4 3SQ\n\nTel: 02890 523 704  \nFax: 02890 523 900  \nEmail: [NIAIC@dhsspsni.gov.uk](mailto:NIAIC@dhsspsni.gov.uk)\n\n### How to report adverse incidents in Northern Ireland\n\nPlease report directly to NIAIC, further information can be found on the [NIAIC website](http://www.dhsspsni.gov.uk/niaic) (external link)  \nFurther information about SABS can be found [on the SABS website](http://sabs.dhsspsni.gov.uk/)(external link)\n\n## Scotland\n\nEnquiries and adverse incident reports in Scotland should be addressed to:\n\nIncident Reporting and Investigation Centre  \nHealth Facilities Scotland  \nNHS National Services Scotland  \nGyle Square  \n1 South Gyle Crescent  \nEdinburgh EH12 9EB\n\nTel: 0131 275 7575  \nFax: 0131 314 0722\n\nEmail: [nss.iric@nhs.net](mailto:nss.iric@nhs.net)\n\n[Health Facilities Scotland Incident Reporting and Investigation Centre (IRIC)Health Facilities Scotland Incident Reporting and Investigation Centre (IRIC)](http://www.hfs.scot.nhs.uk/online-services/incident-reporting-and-investigation-centre-iric/) (external link)\n\n## Wales\n\nEnquiries in Wales should be addressed to:  \n  \nDr Chris Jones  \nMedical Director  \nWelsh Assembly Government  \nCathays Park  \nCardiff CF10 3NQ\n\nTel: 029 2082 3922  \nEmail: [Haz-Aic@wales.gsi.gov.uk](mailto:Haz-Aic@wales.gsi.gov.uk)\n", 
  "raw_html": "<div id=\"inner_tab_content\">\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\r\n\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n\t\t\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\r\n\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n\t\t\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t<h2 class=\"sw\">Device</h2><div class=\"content_section active_content_section\" id=\"Device\">\r\n\t\t\t\t\t\t\t\t<p><span>Dermal filler for breast augmentation.</span></p>\n\n<p><span>Macrolane&#8482; Volume Restoration Factor (VRF).</span></p>\n\n<p><span>Manufactured by Q-Med AB (a Galderma division).</span></p>\n\n<p>Macrolane VRF20 and VRF30 is an injectable filler for volume restoration and body contouring in a range of indications including breast augmentation.</p>\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\r\n\r\n<h2 class=\"sw\">Problem</h2><div class=\"content_section\" id=\"Problem\">\r\n\t\t\t\t\t\t\t\t<span>Use of Macrolane VRF20 and Macrolane VRF30 for breast augmentation can make diagnosis of breast cancer more difficult, particularly with the use of mammography.<br>\n<br>\n</span>The MHRA has been made aware of a <a href=\"#ASSET0\">ASSET_TAG</a> (160Kb) issued in April 2012 to clinicians by Q-Med about the use of Macrolane recommending that it is not used for injection into breasts because it can make diagnosis of breast cancer more difficult, particularly during mammography.<span><br>\n</span><br>\nThe manufacturer has stated:<br>\n&#8216;Macrolane is detectable in mammography, ultrasound examination and MRI examination of the breasts.<br>\n<br>\n<span>Mammograms</span><br>\nA clinical study indicates that the presence of Macrolane may significantly reduce the diagnostic quality of mammograms, since Macrolane will appear as a gray/white shadow in the mammogram. In this case ultrasound can be used as a complementary examination.<br>\n<br>\n<span>Ultrasound</span><br>\nUltrasound can be used to diagnose lumps in the breast after a Macrolane treatment. Ultrasound may also be a complement to mammography at breast screening and diagnosing. Some radiologists explain that Macrolane has a typical appearance in an ultrasound, similar to that of water, but with a snowstorm appearance.&#8217;<br>\n<br>\n<a target=\"_blank\" href=\"http://www.q-medpractitioner.com/International/Macrolane/Radiologists/\">Breast diagnostics and Marolane</a> (external link)<br>\n<br>\nThere is no association with cancer and no safety concerns have been identified for this product. The product remains on the market for use elsewhere in the body. &#160;The manufacturer plans to issue updated instructions for use in due course with updated indications for Macrolane use.<span><br>\n</span>\r\n\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Action</h2><div class=\"content_section\" id=\"Action\">\r\n\t\t\t\t\t\t\t\tDo not use Macrolane for breast augmentation.<br>\n<br>\nHave procedures in place for radiographers to check with patients presenting for breast examination for any history of breast injection. &#160;Staff should request the card (appendix 1) that the patient was given at the time of injection, identifying Macrolane as the product used, and pass it on to the examining radiologist.<br>\n<br>\nWomen may present with concerns that the injected Macrolane has affected mammogram results. GPs may wish to consider referral for repeat imaging. &#160;<br>\n<br>\n<h3>Action by</h3>\n\n<ul>\n<li>Breast surgeons</li>\n\n<li>Cosmetic surgeons</li>\n\n<li>GPs</li>\n\n<li>Mammographers</li>\n\n<li>Plastic surgeons</li>\n\n<li>Radiographers</li>\n\n<li>Radiologists</li>\n</ul>\r\n\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Distribution</h2><div class=\"content_section\" id=\"Distribution\">\r\n\t\t\t\t\t\t\t\t<p>This MDA has been sent to:</p>\n\n<ul>\n<li>NHS trusts in England (chief executives)</li>\n\n<li>Care Quality Commission (CQC) (Headquarters) for information</li>\n\n<li>HSC trusts in Northern Ireland (chief executives)</li>\n\n<li>NHS boards in Scotland (equipment coordinators)</li>\n\n<li>Local authorities in Scotland (equipment coordinators)</li>\n\n<li>NHS boards and trusts in Wales (chief executives)</li>\n\n<li>Primary care trusts in England (chief executives)</li>\n</ul>\n\n<h3>Onward distribution</h3>\n\n<p>Please bring this notice to the attention of relevant employees in your establishment. Below is a suggested list of recipients.</p>\n\n<p><span>Trusts<br>\n</span>CAS and SABS (NI) liaison officers for onward distribution to all relevant staff includingtion to all relevant staff including:</p>\n\n<ul>\n<li>Breast nurse specialists</li>\n\n<li>Breast screening units</li>\n\n<li>Breast surgeons</li>\n\n<li>Clinical governance leads</li>\n\n<li>General surgeons</li>\n\n<li>General surgery</li>\n\n<li>General surgical units, directors of</li>\n\n<li>Mammography units</li>\n\n<li>Medical directors</li>\n\n<li>Medical oncologists</li>\n\n<li>Medical oncology, directors of</li>\n\n<li>Nursing executive directors</li>\n\n<li>MRI units, directors of</li>\n\n<li>Outpatient clinics</li>\n\n<li>Plastic surgeons</li>\n\n<li>Radiographer superintendents</li>\n\n<li>Radiographers</li>\n\n<li>Radiologists</li>\n\n<li>Radiology departments</li>\n\n<li>Radiology directors</li>\n\n<li>Risk managers</li>\n</ul>\n\n<p><span>Primary care trusts</span><br>\nCAS liaison officers for onward distribution to all relevant staff including:</p>\n\n<ul>\n<li>Directors of public health</li>\n\n<li>General practitioners</li>\n</ul>\n\n<br>\n<h3>Independent distribution</h3>\n\n<p><span>Establishments registered with the Care Quality Commission (CQC) (England only)</span></p>\n\n<p>This alert should be read by:</p>\n\n<ul>\n<li>Clinics</li>\n\n<li>Cosmetic surgeons</li>\n\n<li>Hospitals in the independent sector</li>\n\n<li>Independent treatment centres</li>\n\n<li>Private medical practitioners</li>\n</ul>\n\n<p><span>Please note:</span> CQC and OFSTED do not distribute these alerts. Independent healthcare providers and social care providers can sign up to receive MDAs directly from the Department of Health&#8217;s Central Alerting System (CAS) by sending an email to: <a href=\"mailto:safetyalerts@dh.gsi.gov.uk\" added=\"null\">safetyalerts@dh.gsi.gov.uk</a> and requesting this facility.</p>\r\n\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Manufacturer Contact</h2><div class=\"content_section\" id=\"Manufacturer Contact\">\r\n\t\t\t\t\t\t\t\tDavid Wall<br>\nDirector of Sales &amp; Marketing, Q-Med, OTC &amp; Ireland<br>\nGalderma UK &amp; Ireland<br>\nMeridien House<br>\n69-71 Clarendon Road<br>\nWatford<br>\nWD17 1DS<br>\n<br>\nTel: 01923 208 950<br>\nFax: 01923 208 998<br>\nEmail: <a href=\"mailto:David.wall@galderma.com\">David.wall@galderma.com</a>\r\n\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Feedback</h2><div class=\"content_section\" id=\"Feedback\">\r\n\t\t\t\t\t\t\t\t<p>If you have any comments or feedback on this Medical Device Alert please email us at: <a href=\"mailto:dts@mhra.gsi.gov.uk\" added=\"null\">dts@mhra.gsi.gov.uk</a></p>\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\r\n\r\n<h2 class=\"sw\">Appendix</h2><div class=\"content_section\" id=\"Appendix\">\r\n\t\t\t\t\t\t\t\t<a href=\"#ASSET1\">ASSET_TAG</a> (236Kb)\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t<h2 class=\"sw\">England</h2><div class=\"content_section\" id=\"England\">\r\n\t\t\t\t\t\t\t\t\t<p>If you are in England, please send enquiries about this notice to the MHRA, quoting reference number <span>MDA/2012/022</span> or <span>2012/004/023/291/010</span>.</p>\n\n<p><span>Technical aspects</span><br>\nMiss Feza Haque or Mr Ian Smith<br>\nMedicines &amp; Healthcare products Regulatory Agency<br>\nFloor 4<br>\n151 Buckingham Palace Road<br>\nLondon SW1W 9SZ</p>\n\n<p>Tel: 020 3080 7066 / 7306<br>\nFax: 020 8754 3965<br>\nEmail: <a href=\"mailto:feza.haque@mhra.gsi.gov.uk\" added=\"null\">feza.haque@mhra.gsi.gov.uk</a> or <a href=\"mailto:ian.smith@mhra.gsi.gov.uk\" added=\"null\">ian.smith@mhra.gsi.gov.uk</a></p>\n\n<p><span>Clinical aspects<br>\n</span>Dr Nicola Lennard<br>\nMedicines &amp; Healthcare products Regulatory Agency<br>\nFloor 4<br>\n151 Buckingham Palace Road<br>\nLondon SW1W 9SZ</p>\n\n<p>Tel: 020 3080 7126<br>\nFax: 020 8754 3965<br>\nEmail: <a href=\"mailto:nicola.lennard@mhra.gsi.gov.uk\" added=\"null\">nicola.lennard@mhra.gsi.gov.uk</a></p>\n\n<h3>How to report adverse incidents</h3>\n\n<p>Please report via our website: <a href=\"http://www.mhra.gov.uk/Safetyinformation/Reportingsafetyproblems/Devices/index.htm\" added=\"null\">Reporting adverse incidents involving medical devices</a><br>\nFurther information about CAS can be found <a href=\"https://www.cas.dh.gov.uk/Home.aspx\" target=\"_blank\" added=\"null\">on the CAS website</a> (external link)</p>\r\n\t\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Northern Ireland</h2><div class=\"content_section\" id=\"Northern Ireland\">\r\n\t\t\t\t\t\t\t\t\t<p>Alerts in Northern Ireland will continue to be distributed via the NI SABS system.</p>\n\n<p>Enquiries and adverse incident reports in Northern Ireland should be addressed to:</p>\n\n<p>Northern Ireland Adverse Incident Centre<br>\nHealth Estates Investment Group<br>\nRoom 17<br>\nAnnex 6<br>\nCastle Buildings<br>\nStormont Estate<br>\nDundonald BT4 3SQ</p>\n\n<p>Tel: 02890 523 704<br>\nFax: 02890 523 900<br>\nEmail: <a href=\"mailto:NIAIC@dhsspsni.gov.uk\" added=\"null\">NIAIC@dhsspsni.gov.uk</a></p>\n\n<h3>How to report adverse incidents in Northern Ireland</h3>\n\n<p>Please report directly to NIAIC, further information can be found on the <a href=\"http://www.dhsspsni.gov.uk/niaic\" added=\"null\">NIAIC website</a> (external link)<br>\nFurther information about SABS can be found <a href=\"http://sabs.dhsspsni.gov.uk/\" added=\"null\">on the SABS website</a>(external link)</p>\r\n\t\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Scotland</h2><div class=\"content_section\" id=\"Scotland\">\r\n\t\t\t\t\t\t\t\t\t<p>Enquiries and adverse incident reports in Scotland should be addressed to:</p>\n\n<p>Incident Reporting and Investigation Centre<br>\nHealth Facilities Scotland<br>\nNHS National Services Scotland<br>\nGyle Square<br>\n1 South Gyle Crescent<br>\nEdinburgh EH12 9EB</p>\n\n<p>Tel: 0131 275 7575<br>\nFax: 0131 314 0722</p>\n\n<p>Email: <a href=\"mailto:nss.iric@nhs.net\" added=\"null\">nss.iric@nhs.net</a></p>\n\n<p><a href=\"http://www.hfs.scot.nhs.uk/online-services/incident-reporting-and-investigation-centre-iric/\" target=\"_blank\" added=\"null\">Health Facilities Scotland Incident Reporting and Investigation Centre (IRIC)<font class=\"trianglelink\">Health Facilities Scotland Incident Reporting and Investigation Centre (IRIC)</font></a> (external link)</p>\r\n\t\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Wales</h2><div class=\"content_section\" id=\"Wales\">\r\n\t\t\t\t\t\t\t\t\t<p>Enquiries in Wales should be addressed to:<br>\n<br>\nDr Chris Jones<br>\nMedical Director<br>\nWelsh Assembly Government<br>\nCathays Park<br>\nCardiff CF10 3NQ</p>\n\n<p>Tel: 029 2082 3922<br>\nEmail: <a href=\"mailto:Haz-Aic@wales.gsi.gov.uk\" added=\"null\">Haz-Aic@wales.gsi.gov.uk</a></p>\r\n\t\t\t\t\t\t\t\t</div>\r\n</div>\r\n\t\t\t", 
  "title": "Medical Device Alert: Dermal filler for breast augmentation Macrolane\u2122 Volume Restoration Factor (VRF) manufactured by Q-Med AB (a Galderma division) (MDA/2012/022)", 
  "alert_type": [
    "devices"
  ], 
  "medical_specialism": [
    "cosmetic-surgery", 
    "general-practice", 
    "general-surgery", 
    "radiology"
  ]
}